TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03243864
Drug: Ceftazidime-avibactam
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be started on 2.5 gm IV every 8 hours
Study: NCT02172794
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172794
Drug: Placebo to tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172794
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02172794
Drug: Placebo to salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00285779
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept 50 mg twice weekly for 12 weeks
Study: NCT02466919
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. pylori eradication therapy
Study: NCT02466919
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. pylori eradication therapy
Study: NCT02466919
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. pylori eradication therapy
Study: NCT02466919
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. pylori eradication therapy
Study: NCT00791648
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.
Study: NCT03906526
Drug: VTX-2337
Normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motolimod
Study: NCT03906526
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Nivolumab
Study: NCT02550002
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT03502681
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2
Study: NCT03502681
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Days 1, 15 Avelumab (10mg/kg)
Study: NCT02254291
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
Study: NCT02254291
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
Study: NCT02254291
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
Study: NCT01160185
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitacel
Study: NCT01160185
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin monotherapy
Study: NCT01160185
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topotecan
Study: NCT00133705
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 5mg/day by mouth for 6 months
Study: NCT00133705
Drug: Inert Capsule
Normalized name: inert ingredients
DrugBank: Meclinertant (DB06455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT02746315
Drug: HS-20004
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04348474
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
Study: NCT00793520
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily oral administration of Milnacipran for 5 weeks.
Study: NCT02167711
Drug: SIRT Yttrium-90
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03314090
Drug: Silicone Gels
DrugBank: Polysilicone-15 (DB11271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
Study: NCT00066040
Drug: Cervitec chlorhexidine varnish
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00066040
Drug: Duraphat fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00066040
Drug: xylitol gum from Fennobon, Finland
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03889379
Drug: Administration of albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
Study: NCT02260037
Drug: Epinastine nasal
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00772057
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study: NCT01676233
Drug: insulin glargine (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT01676233
Drug: insulin glargine- new formulation (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT00005835
Drug: buthionine sulfoximine
Normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
Study: NCT00005835
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
Study: NCT00004200
Drug: prinomastat
Normalized name: Prinomastat
DrugBank: Prinomastat (DB05100)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004200
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00435448
Drug: Lonidamine
Normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04484857
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Study: NCT00062764
Drug: Actos (Pioglitazone)
Normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
Study: NCT02378480
Drug: Omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection for IV dosing; Tablets for oral dosing
Study: NCT02378480
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion solution for IV dosing; Tablets for oral dosing
Study: NCT00931281
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: capsules, QD or BID, 14 days, ascending doses
Study: NCT00931281
Drug: Placebo for ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: capsule, QD or BID, 14 days
Study: NCT00003249
Drug: carboxyamidotriazole
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003249
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03028701
Drug: Formoterol/Budesonide 12/400 mcg Discair
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
Study: NCT01518413
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
Study: NCT01518413
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
Study: NCT03226691
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
Study: NCT01144650
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
Study: NCT01205516
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
Study: NCT01205516
Drug: Controlled Release Morphine
Normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
Study: NCT03719131
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Receive standard of care nivolumab therapy
Study: NCT03719131
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Receive standard of care ipilimumab therapy
Study: NCT03787654
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
Study: NCT03497377
Drug: 18F-DCFPyL Injection
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03497377
Drug: 18F-NaF
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02385071
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
Study: NCT02385071
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
Study: NCT02385071
Drug: Treatment E
Normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
Study: NCT02385071
Drug: Treatment F
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
Study: NCT03739619
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03739619
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00710099
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: systemic absorption of sildenafil
Study: NCT04321408
Drug: Ziconotide Injection
Normalized name: ziconotide Injection
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal analgesia with Ziconotide
Study: NCT01935947
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01935947
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01935947
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01935947
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01935947
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01935947
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01935947
Drug: Pemetrexed Disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04507763
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with ankylosing spondylitis as provided in real world practice
Study: NCT04154722
Drug: Meropenem Injection
Normalized name: meropenem Injection
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inj meropenum for 10 days
Study: NCT04120870
Drug: Etomidate Injection 0.2 mg/kg
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
Study: NCT04120870
Drug: Ketamine injection 2 mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
Study: NCT00004103
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004103
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004103
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03183310
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
Study: NCT02896205
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
Study: NCT00668629
Drug: Lactic acid (Dermacid)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02164864
Drug: Dabigatran Etexilate 110mg
Normalized name: DABIGATRAN ETEXILATE 110MG CAP,ORAL
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active treatment
Study: NCT02164864
Drug: Warfarin 3mg
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT02164864
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT02164864
Drug: Dabigatran Etexilate 150mg
Normalized name: DABIGATRAN ETEXILATE 150MG CAP,ORAL
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active treatment
Study: NCT02587065
Drug: peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mcg administered subcutaneously (SC) every 2 weeks.
Study: NCT02164864
Drug: Clopidogrel or Ticagrelor
Normalized name: Ticagrelor
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active comparator
Study: NCT02164864
Drug: Warfarin 5mg
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT02164864
Drug: Warfarin 1mg
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT00841139
Drug: Perhexiline
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg o bd
Study: NCT00557193
Drug: Asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, IM, or PO
Study: NCT00557193
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT00557193
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00557193
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00557193
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00557193
Drug: Lestaurtinib
Normalized name: Lestaurtinib
DrugBank: Lestaurtinib (DB06469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00557193
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00557193
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00557193
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00557193
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01758029
Drug: testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
Study: NCT01370148
Drug: conivaptan hydrochloride
Normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00622726
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
Study: NCT01146288
Drug: Furosemide first, then Acetazolamide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.